March 24, 2011 -- Future Medicine Ltd announces today that its new journal Diabetes Management (ISSN 1758-1907) which launched in January 2011 has been selected for coverage by Chemical Abstracts.
Chemical Abstracts, a division of the American Chemical Society, is the most authoritative and comprehensive source for chemical information. CAS databases, including CAS REGISTRYSM, the gold standard for substance information, are curated and quality-controlled by CAS scientists. Visit: www.cas.org to find out more.
Diabetes Management is published on a bi-monthly basis in print and online formats on a rapid publication basis, with articles subject to peer review by three independent assessors. The journal has an international expert authorship and offers commentary and analysis on the advances and current research on the prevention and treatment of diabetes.
Coverage of the journal is overseen by four Associate Editors and an extensive international advisory panel. The four Associate Editors are Denis Daneman, University of Toronto, Canada, Philippe Froguel, Imperial College London, UK, Camillo Ricordi, University of Miami, FL, USA and Jaakko Tuomilehto, University of Helsinki, Finland.
Dr Itamar Raz, a member of the editorial advisory board commented: "Diabetes Management is a much welcomed addition to the multi-disciplined diabetes practitioners worldwide. With its focused articles and brief summaries, it allows a wide variety of time-constrained diabetes professionals to keep abreast of the latest science and technology in this field. We are delighted that the journal has been selected for coverage by Chemical Abstracts which will greatly help globalize its appeal."
Elisa Manzotti, Editorial Director of the Future Medicine series commented, “We are delighted that
Diabetes Management has been accepted for inclusion and will work with the Senior Editors of the journal to ensure that future issues of Diabetes Management keep pace with the huge amount of research being generated.” She continued: “We would like to thank our Senior Editors and Editorial Board for their hard work, intellectual input and guidance in targeting and evaluating topical, pioneering content to ensure inclusion of the journal by Chemical Abstracts.”
Access to Diabetes Management is available on a FREE 30-day trial basis. To apply for your free trial please email
firstname.lastname@example.org quoting reference DMTPR11 to obtain password access.
ABOUT DIABETES MANAGEMENT (www.futuremedicine.com/loi/dmt )
Diabetes Management presents findings, analysis and commentary on the battle with Type I and Type II diabetes. Articles published in Diabetes Management address improvements in current therapeutics and patient compliance together with perspectives on future prospects. Coverage focuses on the key objective of stabilizing blood glucose levels in individuals with either form of the disease, and the associated issues of patient cooperation and education. The journal also reflects the frontiers of current research, such as attempts to recreate pancreatic cells through stem cell technology or islet cell transplantation, the development of a vaccine for Type 1 disease and the potential for biomarkers to be used for the detection. The increasing understanding of the molecular basis of the disease and associated genetics will play an important part in future diabetes management.
Topics covered include:
- Techniques in monitoring blood glucose
- Methods of stabilizing diabetes
- Tailoring nutrition and lifestyle to control diabetes
- Appropriate therapy for all groups including pediatric, geriatric and pregnant patients
- Analysis of success and failure in the latest diabetic medication, including compliance
- Management of diabetic neuropathy, retinopathy and other consequences of poorly managed diabetes
- Recent advances in research to recreate pancreatic cells: immunological considerations and regenerative techniques
- Role of autoimmunity in the development of Type I diabetes
- Tackling mental health problems that develop as a result of the disease
- Epidemiologic and genetic studies
- Pharmacoeconomics and outcomes